Genetic modification controlling organ growth

"Genetic modification controlling organ growth" is not a specific molecular target but rather describes a broad set of **genetic engineering strategies** aimed at regulating the size and development of organs. In biomedical research—especially xenotransplantation—this approach involves using genome-editing technologies such as CRISPR-Cas9 to alter genes that influence how large an animal's organs grow. For example, scientists have edited pig genomes by knocking out the **growth hormone receptor** gene so transplanted pig organs do not continue growing excessively after being placed in human recipients; however, this can sometimes result in unhealthy phenotypes for the donor animal[2]. These modifications are part of broader efforts to make animal-derived organs more compatible with human physiology by addressing both immunological barriers and physiological mismatches like inappropriate post-transplantation growth. This entry does not refer to a single protein, enzyme, or receptor but rather encompasses multiple possible targets within pathways governing cell proliferation and tissue expansion during development[1][5]. As such, it is not considered a canonical therapeutic target itself. This term should be replaced with specific gene/protein names when possible—for example "Growth hormone receptor"—to allow structured data extraction.

Other names

Genetic engineering for organ sizeGenome editing for organ growth controlOrgan size genetic modification

Not applicable; refers to the use of gene editing tools (e.g., CRISPR-Cas9) to modify genes that regulate the growth and development of organs, such as knocking out or altering receptors like the growth hormone receptor in pigs to control post-transplantation organ enlargement.